
Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial
pharmafile | September 2, 2019 | News story | Research and Development, Sales and Marketing | Roche, Xofluza, flu, influenza, pharma
Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment of influenza.
The data showed that, following exposure to a household member who had contracted influenza, Xofluza reduced the risk of patients contracting the disease themselves by 86% compared to placebo: only 1.9% of patients taking the drug developed the flu compared to 13.6% of those taking placebo.
The findings also noted that this benefit remained statistically significant regardless of influenza A subtype, as well as in other high-risk groups: in children under 12, 4.2% taking Xofluza developed the flue compared to 15.5% taking placebo, and in those highly vulnerable to flu-related complications 2.2% developed the disease, compared to 15.4% of placebo patients.
“As the influenza virus can rapidly infect those around us, limiting the spread of infection within households potentially avoids a significant impact on the wider community – a critical step in the global fight against flu,” said Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We are encouraged by the BLOCKSTONE study, the first to show that Xofluza is an effective preventive treatment following exposure to flu and we look forward to sharing these data with health authorities.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Osivax publishes positive results from trial of influenza vaccine candidate
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, …






